News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opexa Therapeutics (OPXA)’ Therapy for Multiple Sclerosis Featured in FOX Television News Story



10/2/2013 10:09:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce that Tcelna has been featured in a FOX Atlanta Channel 5 Newscast titled “New Therapy Could Battle Autoimmune Diseases.” The story by FOX Medical Team reporter Beth Galvin highlights Opexa’s ongoing Phase IIb clinical trial in secondary progressive MS and provides an interview with Dr. Ben Thrower, the Medical Director at the Multiple Sclerosis Institute at Shepherd Center in Atlanta, Georgia, and one of the principal investigators in Opexa's Abili-T clinical trial.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES